Literature DB >> 10025449

Thyroid cancer with concurrent hyperthyroidism.

T C Chao1, J D Lin, L B Jeng, M F Chen.   

Abstract

OBJECTIVE: To study the clinical manifestation, outcome, and factors predicting metastases in patients with thyroid cancer and concurrent hyperthyroidism.
DESIGN: Retrospective study of 37 thyrotoxic patients with differentiated carcinomas of the thyroid who were operated on between 1979 and 1995. The follow-up period ranged from 562 days to 14 years 9 months (mean +/- SE, 2093+/-201 days).
SETTING: University hospital with an annual performance rate of about 700 thyroid operations. PATIENTS: Thyroidectomy was performed in 37 patients (31 women and 6 men), including 33 papillary carcinomas and 4 follicular carcinomas. The mean +/- SE age of the patients was 38.6+/-2.2 years.
RESULTS: The mean +/- SE diameter of tumors was 13.2+/-0.9 mm (range, 2-67 mm). The tumor size in 25 patients (68%) was 10 mm or smaller. Subtotal thyroidectomy (21 patients), total thyroidectomy (8 patients), near-total thyroidectomy (4 patients), and completion thyroidectomy (4 patients) were performed. Twenty-eight patients underwent postoperative sodium iodide I 131 (131I) ablation for thyroid remnant. There was 1 local recurrence, 3 metastases to regional neck lymph nodes, and 3 distant metastases. A patient with follicular carcinoma died of metastases at 3 years 4 months after thyroidectomy. Age, sex, duration of thyrotoxic symptoms, tumor size, histopathological findings, type of goiter, extent of surgery, 131I ablation, and 6-week postoperative serum concentrations of thyroglobulin or thyrotropin were not significant factors in predicting metastases. Serum levels of triiodothyronine and thyroxine before antithyroid treatment in the patients with metastases were significantly higher than in those without metastases.
CONCLUSION: The majority of patients with thyroid cancer and concurrent hyperthyroidism have small carcinomas.

Entities:  

Mesh:

Year:  1999        PMID: 10025449     DOI: 10.1001/archsurg.134.2.130

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  8 in total

1.  Papillary thyroid carcinoma presenting as a solitary soft tissue arm metastasis in an elderly hyperthyroid patient. Case report and review of the literature.

Authors:  Angela Pucci; Monica Suppo; Giovanni Lucchesi; Angela Celeste; Laura Viberti; Riccardo Pellerito; Mauro Papotti
Journal:  Virchows Arch       Date:  2006-03-28       Impact factor: 4.064

Review 2.  Papillary thyroid carcinoma in an autonomous hyperfunctioning thyroid nodule: case report and review of the literature.

Authors:  Hala M Tfayli; Lisa A Teot; Justin A Indyk; Selma Feldman Witchel
Journal:  Thyroid       Date:  2010-09       Impact factor: 6.568

3.  Thyroid cancer in Plummer's disease.

Authors:  Queenie Guinto Ngalob; Iris Thiele Isip-Tan
Journal:  BMJ Case Rep       Date:  2013-03-01

4.  Risk stratification of 282 differentiated thyroid cancers found incidentally in 1369 total thyroidectomies according to the 2015 ATA guidelines; implications for management and treatment.

Authors:  I Christakis; S Dimas; I D Kafetzis; N Roukounakis
Journal:  Ann R Coll Surg Engl       Date:  2018-02-27       Impact factor: 1.891

5.  Predictive factors of thyroid cancer in patients with Graves' disease.

Authors:  Meng Ren; Mu Chao Wu; Chang Zhen Shang; Xiao Yi Wang; Jing Lu Zhang; Hua Cheng; Ming Tong Xu; Li Yan
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

6.  Hyperfunctioning solid/trabecular follicular carcinoma of the thyroid gland.

Authors:  Luca Giovanella; Fabrizio Fasolini; Sergio Suriano; Luca Mazzucchelli
Journal:  J Oncol       Date:  2010-08-16       Impact factor: 4.375

7.  Prognosis of multifocal papillary thyroid carcinoma.

Authors:  Sheng-Fong Kuo; Shu-Fu Lin; Tzu-Chieh Chao; Chuen Hsueh; Kun-Ju Lin; Jen-Der Lin
Journal:  Int J Endocrinol       Date:  2013-12-30       Impact factor: 3.257

8.  Toxic thyroid carcinoma: A new case.

Authors:  C Gopalakrishnan Nair; Pradeep Jacob; Misha Babu; Riju Menon
Journal:  Indian J Endocrinol Metab       Date:  2012-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.